Search - tctmd.com

Displaying 1 - 20 of 279

Sort: Relevancy | Date

Olezarsen Doesn’t Lower Plaque Volume: Essence-TIMI 73b

News Conference News ACC 2026

Olezarsen Doesn’t Lower Plaque Volume: Essence-TIMI 73b

Yael L. Maxwell

April 01, 2026

SMART-DECISION: Stopping Beta-blockers Post-MI Safe in Stable Patients

News Conference News ACC 2026

SMART-DECISION: Stopping Beta-blockers Post-MI Safe in Stable Patients

Michael O'Riordan

March 30, 2026

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

News Conference News ACC 2026

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

Yael L. Maxwell

March 28, 2026

What’s Going to Be Hot at ACC 2026

News Conference News ACC 2026

What’s Going to Be Hot at ACC 2026

Michael O'Riordan

March 20, 2026

TAVR-MET: Early Signs Point to Less Postprocedural Valve Dysfunction With Tirzepatide

News Conference News CRT 2026

TAVR-MET: Early Signs Point to Less Postprocedural Valve Dysfunction With Tirzepatide

March 19, 2026

CRT 2026: What to Expect in Washington, DC

News Conference News CRT 2026

CRT 2026: What to Expect in Washington, DC

March 04, 2026

Loberamisal Scores a Rare Win for Stroke Neuroprotection

News Conference News ISC 2026

Loberamisal Scores a Rare Win for Stroke Neuroprotection

February 12, 2026

OPTION: IV Tenecteplase Boosts Outcomes Late After Non-LVO Stroke

News Conference News ISC 2026

OPTION: IV Tenecteplase Boosts Outcomes Late After Non-LVO Stroke

February 11, 2026

CHOICE-2 Bolsters Intra-arterial Lytics After Stroke Thrombectomy

News Conference News ISC 2026

CHOICE-2 Bolsters Intra-arterial Lytics After Stroke Thrombectomy

February 06, 2026

Olezarsen Cuts Triglycerides, Pancreatitis Risk in Severe Hypertriglyceridemia

News Conference News AHA 2025

Olezarsen Cuts Triglycerides, Pancreatitis Risk in Severe Hypertriglyceridemia

Michael O'Riordan

November 14, 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

News Conference News AHA 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

Michael O'Riordan

November 08, 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

News Conference News AHA 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

November 08, 2025

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

News Conference News ESC 2025

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

Michael O'Riordan

September 10, 2025

Olezarsen Brings Moderately High Triglycerides Under Control: Essence-TIMI 73b

News Conference News ESC 2025

Olezarsen Brings Moderately High Triglycerides Under Control: Essence-TIMI 73b

August 31, 2025

BaxHTN: Baxdrostat Lowers BP in Uncontrolled and Resistant Hypertension

News Conference News ESC 2025

BaxHTN: Baxdrostat Lowers BP in Uncontrolled and Resistant Hypertension

August 31, 2025

Digitoxin Cuts Risk in Well-Treated HFrEF Patients: DIGIT-HF

News Conference News ESC 2025

Digitoxin Cuts Risk in Well-Treated HFrEF Patients: DIGIT-HF

Michael O'Riordan

August 29, 2025

AI-Based Coronary Plaque Analysis Can Inform Management Beyond CCTA: DECIDE Registry

News Conference News SCCT 2025

AI-Based Coronary Plaque Analysis Can Inform Management Beyond CCTA: DECIDE Registry

Yael L. Maxwell

July 21, 2025

Less Intense Checks May Be OK After IV Thrombolysis for Stroke: OPTIMISTmain

News Conference News ESOC 2025

Less Intense Checks May Be OK After IV Thrombolysis for Stroke: OPTIMISTmain

May 28, 2025

ASSET-IT: Tirofiban Boosts Outcomes After IV Thrombolysis for Acute Stroke

News Conference News ESOC 2025

ASSET-IT: Tirofiban Boosts Outcomes After IV Thrombolysis for Acute Stroke

May 27, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.